Chemed (NYSE:CHE) Releases FY 2026 Earnings Guidance

Chemed (NYSE:CHE) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 24.000-24.75 for the period, compared to the consensus estimate of 23.480. The company issued revenue guidance of -.

Chemed Stock Up 2.8%

NYSE CHE traded up $10.27 during trading hours on Thursday, reaching $383.42. 257,430 shares of the company were exchanged, compared to its average volume of 227,753. Chemed has a 1 year low of $365.20 and a 1 year high of $583.96. The business’s 50 day simple moving average is $405.82 and its 200-day simple moving average is $426.70. The stock has a market capitalization of $5.60 billion, a P/E ratio of 20.87, a P/E/G ratio of 1.48 and a beta of 0.49.

Chemed (NYSE:CHE) last posted its earnings results on Thursday, April 23rd. The company reported $5.65 earnings per share for the quarter, topping the consensus estimate of $5.39 by $0.26. The firm had revenue of $657.51 million during the quarter, compared to the consensus estimate of $659.22 million. Chemed had a net margin of 10.48% and a return on equity of 25.66%. Chemed has set its FY 2026 guidance at 24.000-24.75 EPS. As a group, sell-side analysts anticipate that Chemed will post 21.92 earnings per share for the current year.

Chemed Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, March 13th. Stockholders of record on Monday, February 23rd were paid a $0.60 dividend. The ex-dividend date was Monday, February 23rd. This represents a $2.40 annualized dividend and a dividend yield of 0.6%. Chemed’s dividend payout ratio (DPR) is presently 13.06%.

Analyst Ratings Changes

Several research firms have recently weighed in on CHE. Weiss Ratings downgraded shares of Chemed from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, April 13th. Zacks Research downgraded shares of Chemed from a “hold” rating to a “strong sell” rating in a research note on Wednesday, March 4th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $422.00 target price (down from $572.00) on shares of Chemed in a research note on Friday, February 27th. Oppenheimer reduced their price objective on shares of Chemed from $580.00 to $500.00 and set an “outperform” rating for the company in a research note on Friday, February 27th. Finally, Jefferies Financial Group cut shares of Chemed from a “buy” rating to a “hold” rating in a research note on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $498.00.

Insider Transactions at Chemed

In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of Chemed stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $403.18, for a total transaction of $806,360.00. Following the completion of the sale, the chief executive officer directly owned 93,719 shares in the company, valued at $37,785,626.42. The trade was a 2.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 3.29% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Chemed

Hedge funds have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Chemed by 58.5% in the 3rd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 1,217 shares of the company’s stock worth $545,000 after acquiring an additional 449 shares during the last quarter. Entropy Technologies LP lifted its holdings in shares of Chemed by 35.1% in the 4th quarter. Entropy Technologies LP now owns 1,216 shares of the company’s stock worth $520,000 after acquiring an additional 316 shares during the last quarter. Aviva PLC lifted its holdings in shares of Chemed by 7.2% in the 4th quarter. Aviva PLC now owns 1,130 shares of the company’s stock worth $483,000 after acquiring an additional 76 shares during the last quarter. Vident Advisory LLC lifted its holdings in shares of Chemed by 28.3% in the 2nd quarter. Vident Advisory LLC now owns 947 shares of the company’s stock worth $461,000 after acquiring an additional 209 shares during the last quarter. Finally, EP Wealth Advisors LLC bought a new stake in shares of Chemed in the 4th quarter worth approximately $451,000. 95.85% of the stock is currently owned by institutional investors.

About Chemed

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.